BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb (BMY) announced on Friday that its drug, evaluated for myelofibrosis-associated anemia, did not meet its ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

The first half of 2025 has been topsy-turvy for Bristol Myers BMY. Shares of this biotech giant have lost 16.3% year to date compared with the industry ’s decline of 2.7%. The stock has also ...

Inflation Shock (2022) BMY stock declined 40.2% from a high of $81.13 on 2 December 2022 to $48.48 on 21 November 2023, compared to a peak-to-trough drop of 25.4% for the S&P 500 ...